ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up Zacks Equity Research Aug 18, 2026 argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up Zacks Equity Research Aug 7, 2026 HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
What Makes Argenx (ARGX) a New Buy Stock Zacks Equity Research Aug 4, 2026 Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FTRE vs. ARGX: Which Stock Is the Better Value Option? Zacks Equity Research Jul 31, 2026 FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE vs. ARGX: Which Stock Is the Better Value Option? Zacks Equity Research Jul 31, 2026 FTRE vs. ARGX: Which Stock Is the Better Value Option?
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? Zacks Equity Research Jul 29, 2026 Here is how argenex SE (ARGX) and Agilent Technologies (A) have performed compared to their sector so far this year.
